| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
|
Pearson, Andrew D J
|
|
|
23 |
11 |
p. 1354-1357
|
artikel
|
| 2 |
Accelerating the integration of China into the global development of innovative anticancer drugs
|
Huang, Huiyao
|
|
|
23 |
11 |
p. e515-e520
|
artikel
|
| 3 |
Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials
|
Fiteni, Frédéric
|
|
|
23 |
11 |
p. e480
|
artikel
|
| 4 |
Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study
|
Qin, Na
|
|
|
23 |
11 |
p. 1465-1474
|
artikel
|
| 5 |
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
|
Wainberg, Zev A
|
|
|
23 |
11 |
p. 1430-1440
|
artikel
|
| 6 |
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial
|
Spinazzi, Eleonora F
|
|
|
23 |
11 |
p. 1409-1418
|
artikel
|
| 7 |
Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma
|
Young, Jacob S
|
|
|
23 |
11 |
p. 1347-1348
|
artikel
|
| 8 |
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
|
Ganguly, Shuvadeep
|
|
|
23 |
11 |
p. e488
|
artikel
|
| 9 |
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
|
Tarigopula, Vivek
|
|
|
23 |
11 |
p. e487
|
artikel
|
| 10 |
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
|
Meirson, Tomer
|
|
|
23 |
11 |
p. e489
|
artikel
|
| 11 |
Consolidation in US health care negatively impacts cancer care
|
Nelson, Roxanne
|
|
|
23 |
11 |
p. 1358-1359
|
artikel
|
| 12 |
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
|
Shiota, Masaki
|
|
|
23 |
11 |
p. 1345-1347
|
artikel
|
| 13 |
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
|
Merseburger, Axel S
|
|
|
23 |
11 |
p. 1398-1408
|
artikel
|
| 14 |
Correction to Lancet Oncol 2022; 23: 1240–43
|
|
|
|
23 |
11 |
p. e492
|
artikel
|
| 15 |
Correction to Lancet Oncol 2022; 23: e449
|
|
|
|
23 |
11 |
p. e492
|
artikel
|
| 16 |
Correction to Lancet Oncol 2022; 23: e450–58
|
|
|
|
23 |
11 |
p. e492
|
artikel
|
| 17 |
Correction to Lancet Oncol 2022; 23: e469–78
|
|
|
|
23 |
11 |
p. e492
|
artikel
|
| 18 |
Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study
|
Man, Irene
|
|
|
23 |
11 |
p. 1419-1429
|
artikel
|
| 19 |
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries
|
Nolte, Ellen
|
|
|
23 |
11 |
p. e502-e514
|
artikel
|
| 20 |
First, do no harm: risk of secondary cancer after breast cancer treatment
|
Rugo, Hope S
|
|
|
23 |
11 |
p. 1350-1352
|
artikel
|
| 21 |
Hope for Africa's New Public Health Order to fight cancer
|
Makoni, Munyaradzi
|
|
|
23 |
11 |
p. 1362
|
artikel
|
| 22 |
Increase in vaping and e-cigarette use by children in Malaysia
|
Das, Manjulika
|
|
|
23 |
11 |
p. 1360
|
artikel
|
| 23 |
Limitations of the radiosensitivity index as a direct prognostic marker
|
Grimes, David Robert
|
|
|
23 |
11 |
p. 1352-1353
|
artikel
|
| 24 |
Metastatic epithelioid aortic angiosarcoma
|
Elkhatib, Wiaam
|
|
|
23 |
11 |
p. e521
|
artikel
|
| 25 |
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
|
Long, Georgina V
|
|
|
23 |
11 |
p. 1378-1388
|
artikel
|
| 26 |
Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?
|
Sartor, Oliver
|
|
|
23 |
11 |
p. 1344-1345
|
artikel
|
| 27 |
Progress and remaining challenges for cancer control in the Gulf Cooperation Council
|
Alhomoud, Samar
|
|
|
23 |
11 |
p. e493-e501
|
artikel
|
| 28 |
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
|
Buteau, James P
|
|
|
23 |
11 |
p. 1389-1397
|
artikel
|
| 29 |
Pursuing excellence in cancer care in Pakistan
|
Yusuf, Muhammed Aasim
|
|
|
23 |
11 |
p. 1365-1366
|
artikel
|
| 30 |
Rezvilutamide for metastatic hormone-sensitive prostate cancer
|
Singh, Kirti
|
|
|
23 |
11 |
p. e490
|
artikel
|
| 31 |
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply
|
Ye, Dingwei
|
|
|
23 |
11 |
p. e491
|
artikel
|
| 32 |
Should chemotherapy-free treatment be offered for advanced oesophageal squamous-cell carcinoma?
|
Smyth, Elizabeth C
|
|
|
23 |
11 |
p. 1363-1364
|
artikel
|
| 33 |
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial
|
Papachristofilou, Alexandros
|
|
|
23 |
11 |
p. 1441-1450
|
artikel
|
| 34 |
Strengthening cancer control in Africa gathers momentum
|
The Lancet Oncology,
|
|
|
23 |
11 |
p. 1343
|
artikel
|
| 35 |
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
|
Bidard, François-Clément
|
|
|
23 |
11 |
p. 1367-1377
|
artikel
|
| 36 |
Symptomatic melanoma CNS metastases in the TRICOTEL study
|
Schmitt, Andreas M
|
|
|
23 |
11 |
p. e481
|
artikel
|
| 37 |
Symptomatic melanoma CNS metastases in the TRICOTEL study – Authors' reply
|
Dummer, Reinhard
|
|
|
23 |
11 |
p. e482
|
artikel
|
| 38 |
Thoracic CT follow-up after non-small-cell lung cancer resection
|
Heuvelmans, Marjolein A
|
|
|
23 |
11 |
p. e483
|
artikel
|
| 39 |
Thoracic CT follow-up after non-small-cell lung cancer resection
|
Goto, Taichiro
|
|
|
23 |
11 |
p. e485
|
artikel
|
| 40 |
Thoracic CT follow-up after non-small-cell lung cancer resection
|
Woodard, Gavitt A
|
|
|
23 |
11 |
p. e484
|
artikel
|
| 41 |
Thoracic CT follow-up after non-small-cell lung cancer resection – Authors' reply
|
Westeel, Virginie
|
|
|
23 |
11 |
p. e486
|
artikel
|
| 42 |
Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study
|
Veiga, Lene H S
|
|
|
23 |
11 |
p. 1451-1464
|
artikel
|
| 43 |
What is the best way to treat patients with stage IIA or IIB seminoma?
|
Giannatempo, Patrizia
|
|
|
23 |
11 |
p. 1349-1350
|
artikel
|
| 44 |
WHO urges immediate action to tackle non-communicable diseases
|
Das, Manjulika
|
|
|
23 |
11 |
p. 1361
|
artikel
|
Tijdschrift beschrijving